Invokana Lawsuit: Highlight Possible Heart Attack and Stroke Link

April 19, 2016 – – TheProductLawyers.com comments on the results of clinical trials that have been conducted on a type-2 diabetes drug known as Invokana. Results from these clinical trials link Invokana with the increased risk of heart attacks among patients taking the drug. This connection is strongest in the first 30 days of treatment according to the trials.

In 2013, Invokana was approved by the U.S. Food and Drug Administration. This was the first SGLT2 inhibitor drug class medication released to the public. The clinical trials that were performed on the drug showed that more than one patient suffered from a heart attack or stroke within the first 30 days of the treatment regimen. However, following that 30 day period, the risks seemed to level out. The conductors of the clinical trial have not yet determined why this risk occurs. They stated it may have something to do with patient cholesterol levels, as cholesterol levels are recognized to elevate with many diabetes drugs.

The FDA has addressed safety concerns with Invokana by releasing public safety communications and asking the drug manufacturer, Janssen Pharmaceuticals (a Johnson & Johnson division), to update the warning label regarding other drug side effects. However, the heart attack issue has not been addressed in this way. According to the New York Times, the FDA has required the company to perform post-marketing studies to better find out if Invokana increases heart attack and stroke risks.

“We are currently investigating several cases where individuals who took an SGLT2, such as Invokana, Farxiga or Jardiance, subsequently were diagnosed with diabetic ketoacidosis, kidney complications, heart attack and stroke. If we prove that these complications were caused by the drug, we look forward to aggressively pursuing the rights of our clients and recovering just compensation for their pain and suffering, and for what their families may have had to endure,” stated attorney Laurence Banville, a defective drug and product lawyer and sponsor of TheProductLawyers.com.

For more information about the Invokana lawsuits, or this press release, please contact TheProductLawyers.com on 888-997-3792.

###

Contact TheProductLawyers.com:

Banville Law
888-997-3792
info@banvillelaw.com
165 West End Ave #1h,
New York, NY 10023

ReleaseID: 60009399